Quick Takeaways
- BIAF - bioAffinity Technologies, Inc. has 17 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of bioAffinity Technologies, Inc.
- Symbol
- BIAF, BIAFW on Nasdaq
- Location
- San Antonio, TX
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 19 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
bioAffinity Technologies, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Gary D. Rubin | Director, 10%+ Owner | $4,586,464 | Mixed | 01 Jul 2024 | ||
| Steven Girgenti | Executive Chairman, Director | $2,846,638 | Mixed | 10 Jan 2025 | ||
| Nathan M. Perlmutter | 10%+ Owner | $2,213,386 | Mixed | 06 Sep 2022 | ||
| Roby Joyce | Director | $1,721,825 | Mixed | 01 Jul 2024 | ||
| Maria Zannes | President & CEO, Director | $644,803 | Mixed | 10 Jan 2025 | ||
| Robert A. Anderson | Director | $434,430 | Mixed | 01 Jul 2024 | ||
| Peter S. Knight | Director | $311,256 | Mixed | 01 Jul 2024 | ||
| James Michael Edwards | VP and CFO | $301,983 | Mixed | 10 Jan 2025 | ||
| Stuart Diamond | Director | $262,583 | Mixed | 01 Jul 2024 | ||
| Mohsin Y. Meghji | Director | $162,411 | Mixed | 01 Oct 2023 | ||
| Jamie Platt | Director | $145,082 | Mixed | 01 Jul 2024 | ||
| Michael Philip Dougherty | Chief Financial Officer | $124,620 | Mixed | 31 Jan 2024 | ||
| Timothy P. Zannes | Secretary, EVP, Gen. Counsel | $119,000 | Mixed | 10 Jan 2025 | ||
| Vivienne I. Rebel | Chief Sci. & Med. Officer, EVP | $68,417 | Mixed | 31 Jan 2024 | ||
| Xavier T. Reveles | Chief Operating Officer | $30,102 | Mixed | 10 Jan 2025 | ||
| Roberto Rios | Director | $208 | Mixed | 12 Aug 2025 | ||
| John J. Oppenheimer | Director | Mixed | 12 Aug 2025 |
Top shareholders of bioAffinity Technologies, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Gary D. Rubin |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
1,730,741
|
$4,586,464 | — | 01 Jul 2024 | |
| Steven Girgenti |
3/4/5
|
Executive Chairman, Director |
—
class O/S missing
|
1,089,017
|
$2,846,638 | — | 10 Jan 2025 | |
| Nathan M. Perlmutter |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
399,653
mixed-class rows
|
$2,213,386 | — | 06 Sep 2022 | |
| Roby Joyce |
3/4/5
|
Director |
—
class O/S missing
|
649,745
|
$1,721,825 | — | 01 Jul 2024 | |
| Richard K. Crumly |
13D/G
|
— |
11%
|
3,213,777
|
$1,446,200 | $0 | 07 May 2025 | |
| Maria Zannes |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
280,359
|
$644,803 | — | 10 Jan 2025 | |
| Robert A. Anderson |
3/4/5
|
Director |
—
class O/S missing
|
163,936
|
$434,430 | — | 01 Jul 2024 | |
| Peter S. Knight |
3/4/5
|
Director |
—
class O/S missing
|
117,455
|
$311,256 | — | 01 Jul 2024 | |
| James Michael Edwards |
3/4/5
|
VP and CFO |
—
class O/S missing
|
120,128
|
$301,983 | — | 10 Jan 2025 | |
| Stuart Diamond |
3/4/5
|
Director |
—
class O/S missing
|
99,088
|
$262,583 | — | 01 Jul 2024 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.7%
|
55,543
|
$212,730 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
48,293
|
$184,961 | — | 31 Mar 2026 | |
| J. Safra Sarasin Holding AG |
13F
|
Company |
2.1%
|
42,600
|
$164,010 | — | 31 Mar 2026 | |
| Mohsin Y. Meghji |
3/4/5
|
Director |
—
class O/S missing
|
109,737
|
$162,411 | — | 01 Oct 2023 | |
| Jamie Platt |
3/4/5
|
Director |
—
class O/S missing
|
54,748
|
$145,082 | — | 01 Jul 2024 | |
| Michael Philip Dougherty |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
84,203
|
$124,620 | — | 31 Jan 2024 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
1.5%
|
31,071
|
$119,002 | — | 31 Mar 2026 | |
| Timothy P. Zannes |
3/4/5
|
Secretary, EVP, Gen. Counsel |
—
class O/S missing
|
54,765
|
$119,000 | — | 10 Jan 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1.2%
|
24,413
|
$93,500 | — | 31 Mar 2026 | |
| Vivienne I. Rebel |
3/4/5
|
Chief Sci. & Med. Officer, EVP |
—
class O/S missing
|
46,228
|
$68,417 | — | 31 Jan 2024 | |
| UBS Group AG |
13F
|
Company |
—
mixed-class rows
|
55,323
mixed-class rows
|
$56,177 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
0.71%
|
14,386
|
$55,098 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.63%
|
12,725
|
$48,737 | — | 31 Mar 2026 | |
| Xavier T. Reveles |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
41,943
|
$30,102 | — | 10 Jan 2025 | |
| Clear Street Group Inc. |
13F
|
Company |
—
class O/S missing
|
54,927
|
$24,854 | — | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.1%
|
2,063
|
$7,901 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
class O/S missing
|
19,850
|
$6,551 | — | 31 Mar 2026 | |
| Ameritas Advisory Services, LLC |
13F
|
Company |
0.05%
|
1,000
|
$3,830 | — | 31 Mar 2026 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
—
class O/S missing
|
11,013
|
$3,634 | — | 31 Mar 2026 | |
| IFP Advisors, Inc |
13F
|
Company |
0.04%
|
833
|
$3,190 | — | 31 Mar 2026 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
57
|
$218 | — | 31 Mar 2026 | |
| Roberto Rios |
3/4/5
|
Director |
0%
|
833
|
$208 | — | 12 Aug 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
3
|
$11 | — | 31 Mar 2026 | |
| Caitong International Asset Management Co., Ltd |
13F
|
Company |
0%
|
1
|
$4 | — | 31 Mar 2026 | |
| BIGGER CAPITAL FUND L P |
13D/G
|
Bigger Michael |
5.8%
|
117,364
|
— | $0 | 29 Sep 2025 |
Recent Insider Transactions by Companies or Individuals for bioAffinity Technologies, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Roberto Rios | BIAF | Common Stock | 0 | 833 | 12 Aug 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.